Low-dose 'natural' alpha-interferon in B-cell derived chronic lymphocytic leukemia

G. Pozzato, F. Franzin, M. Moretti, P. Tulissi, P. Pecorari, M. Melato, T. Zacchi, P. Evangelisti, L. Campanacci

Research output: Contribution to journalArticlepeer-review


Background. Alpha-interferon (alpha-IFN) was found to have a good antiproliferative effect in early stage chronic lymphocytic leukemia (CLL), but recombinant alpha-IFN administration may induce serious side effects. Therefore low-dose 'natural' IFN was evaluated in terms of efficacy and safety. Methods. Fifteen patients affected by stage A (according to Binet) B-CLL underwent the treatment: natural IFN 1 MU three times a week for 6 months. Results. Overall lymphocyte count decreased from 13.050 ± 3.200 to 7.500 ± 2.940 within 6 months. One patient did not respond to IFN therapy. No one complained of side effects. Conclusion: Low dose 'natural' alpha-IFN seems useful and well tolerated in CLL, but the potential curative role of IFN in CLL remains to be established.

Original languageEnglish
Pages (from-to)413-417
Number of pages5
Issue number5
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Low-dose 'natural' alpha-interferon in B-cell derived chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this